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Summary
Objective: Articular cartilage repair remains a major obstacle in tissue engineering. We recently developed a novel tool for articular cartilage
repair, consisting of a triple composite of an interconnected porous hydroxyapatite (IP-CHA), recombinant human bone morphogenetic
protein-2 (rhBMP-2), and a synthetic biodegradable polymer [poly-D,L-lactic acid/polyethylene glycol (PLA-PEG)] as a carrier for rhBMP-2. In
the present study, we evaluated the capacity of the triple composite to induce the regeneration of articular cartilage.
Methods: Full-thickness cartilage defects were created in the trochlear groove of 52 New Zealand White rabbits. Sixteen defects were ﬁlled
with the bone morphogenetic protein (BMP)/PLAePEG/IP-CHA composite (group I), 12 with PLAePEG/IP-CHA (group II), 12 with IP-CHA
alone (group III), and 12 were left empty (group IV). The animals were killed 1, 3, and 6 weeks after surgery, and the gross appearance of the
defect sites was assessed. The harvested tissues were examined radiographically and histologically.
Results: One week after implantation with the BMP/PLAePEG/IP-CHA composite (group I), vigorous repair had occurred in the subchondral
defect. It contained an agglomeration of mesenchymal cells which had migrated from the surrounding bone marrow either directly, or indirectly
via the interconnecting pores of the IP-CHA scaffold. At 6 weeks, these defects were completely repaired. The regenerated cartilage
manifested a hyaline-like appearance, with a mature matrix and a columnar organization of chondrocytes.
Conclusions: The triple composite of rhBMP-2, PLA-PEG, and IP-CHA promotes the repair of full-thickness articular cartilage defects within as
short a period as 3 weeks in the rabbit model. Hence, this novel cell-free implant biotechnology could mark a new development in the ﬁeld of
articular cartilage repair.
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Cartilage
Repair
SocietyIntroduction
To date, the myth ‘‘once destroyed, cartilage cannot be
repaired’’ has yet to be dispelled1. Mature articular cartilage
cannot heal spontaneously owing to its low mitotic activity,
which contrasts to the rapid rate of chondrocytic mitosis
during normal cartilage growth.
Recently, several researchers have attempted to utilize
culture-expanded autologous chondrocytes in combination
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Received8November2004; revisionaccepted20December2004.405with collagen sponges or ﬁbrin glue to effect the repair of
cartilage defects2,3. However, the results were either
unsatisfactory or, if satisfactory, were achieved only after
a lengthy wait for the regeneration of hyaline cartilage2,4.
These poor results may reﬂect the characteristics of the
transplantation technique, which involves the application of
cartilage-derived cells to the defect5.
Mesenchymal stem cells (MSCs) isolated from bone
marrow have the ability to differentiate into chondrocytes,
osteoblasts and other connective tissue cells of mesenchy-
mal origin when cultured under appropriate in vitro
conditions6,7. In an effort to exploit the pluripotentiality of
MSCs, MSC-based repair strategies have been instigated
in rabbits and goats, but with limited success8,9. Clinically,
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arthroplasty and osteochondral drilling, have been widely
used and considered to be partially successful10,11. These
techniques are based on the concept that intentional
damage to the subchondral bone recruits MSCs to the
defect, thereby promoting cartilage repair.
A potentially powerful alternative approach for cartilage
regeneration is the local administration of bone morphoge-
netic proteins (BMPs), which are members of the trans-
forming growth factor-b superfamily. BMPs have been
shown to regulate and promote the growth and differentiation
of chondrocytes, osteoblasts and MSCs12,13. Indeed, re-
combinant human bone morphogenetic protein-2 (rhBMP-2)
can stimulate the in vitro synthesis of components of the
chondrocytic matrix, such as proteoglycans and type-II
collagen14e16. Furthermore, BMPs are known to induce the
condensation of MSCs when administered in vivo17e19.
Inorganic biomaterials, such as carbon ﬁbers20, collagen
scaffolds2,21, absorbable polymers22,23, and hydroxyapa-
tite24,25, have been used for articular cartilage repair. Some
success has been achieved in the repair of small
osteochondral defects, but no widely accepted method
exists for the complete healing of hyaline cartilage. The
cause of the failure lies not in the nature of the biomaterial
itself but in its structure, which is not regulated three-
dimensionally.
In the present study, we attempted to combine two
distinct approaches: the strong induction of subchondral
bone regeneration, with a view to recruiting bone-marrow
MSCs to the osteochondral defect; and the appropriate
local delivery of rhBMP-2 to induce chondrocytic differen-
tiation and to stimulate matrix production by the chondro-
cytes. To instigate these two approaches simultaneously,
we developed a combined biomaterial, which consists of
a synthetic hydroxyapatite with an interconnected porous
structure (IP-CHA), and a synthetic bioabsorbable polymer,
namely, PLAePEG (poly-D,L-lactic acidepolyethylene gly-
col block copolymer). In this system, PLAePEG serves as
a drug-delivery carrier, which permits the ideal release of
rhBMP-2 over a period of about 3 weeks26e29. IP-CHA is
made from hydroxyapatite, which is a bioactive ceramic with
osteoconductive properties30,31. In addition, IP-CHA has
a ﬁnely organized, three-dimensional interconnecting pore
structure. The material is highly porous (porosity: 75%) and
the pore size (150 mm) is appropriate for bone formation.
The large interconnecting channels (average diameter:
40 mm) permit the easy penetration of tissue into the deep
pores30. Owing to these structural properties, IP-CHA can
itself induce local bone repair processes30,32,33. The
interconnecting pore structure of the material also permits
its easy impregnation with cytokines or growth factors borne
by an appropriate delivery system.
The rationale behind the selection of key experimental
design parameters was as follows: Skeletally immature
adolescent rabbits (4e6 months old and 2.5e3.0 kg in
weight) were selected because the ability of articular
cartilage to repair depends mostly on the bone-marrow
MSCs, which are metabolically more active and have
a higher capacity to induce repair in an immature model.
The decision to use full-thickness defects with a diameter of
4 mm and a depth of 6 mm was based on the results of
previous studies. In rabbits, partial-thickness defects do not
heal spontaneously, whereas full-thickness ones with a di-
ameter less than 3 mm do, and the repair tissue is
composed either of hyaline- or of ﬁbrocartilage34e36. Hence,
it was necessary to establish a model in which this upper
limit for spontaneous repair was exceeded.In the present study, we demonstrate the capacity of the
triple composite of rhBMP-2, PLA-PEG, and IP-CHA to
effect articular cartilage repair. The goal was to achieve the
repair of full-thickness articular cartilage defects in rabbits in
as short a time as possible, with the ultimate view of
inducing the repair of similar lesions in humans; speciﬁcally,
those generated during osteoarthritis, rheumatoid arthritis,
and osteochondritis dissecans.
Materials and methods
PREPARATION OF IMPLANTS
IP-CHA was synthesized by Toshiba Ceramics Co., Ltd.
(Kanagawa, Japan), as previously described30. In short, we
adopted a ‘‘foam gel’’ technique, which involves two unique
steps: a foaming step and a crosslinking step. During the
foaming step, the hydroxyapatite slurry is mixed with
a foaming agent (polyethyleneimine, 40% by weight).
During the crosslinking (polymerization) step, the foam-like
hydroxyapatite slurry is rapidly gelatinized using a water-
soluble crosslinking agent (a poly-functional epoxy com-
pound)30.
rhBMP-2, which is produced by the Genetics Institute
(Cambridge, MA) and was given to us by Yamanouchi
Pharmaceutical Co., Ltd. (Ibaraki, Japan), was dissolved in
buffer (5 mM glutamic acid, 2.5% glycine, 0.5% sucrose,
and 0.01% Tween 80) at a concentration of 1 mg/ml. The
solution was then ﬁlter-sterilized. Two-hundred mg of
PLAePEG [molecular weight (MW)Z 11,400, dispersity
(Mw/Mn)Z 1.1 (Taki Chemical Research Laboratory, Ka-
nagawa, Japan)] was dissolved in 1 ml of acetone. To
prepare a single implant sample, a 25 ml aliquot of the
PLAePEG mass (5 mg) was mixed with a 20 ml sample of
rhBMP-2 (20 mg). The specimen of IP-CHA (4 mm in
diameter and 4 mm in height) was immersed in the mixture
and the solvent was evaporated in a centrifuge/evaporator.
The resulting BMP/PLAePEG/IP-CHA composite was
sterilized with ethylene oxide gas for 24 h on the day
preceding implantation.
IN VITRO RELEASE KINETICS OF RHBMP-2
The release of rhBMP-2 from the BMP/PLAePEG/
IP-CHA composite was measured using a quantitative
sandwich enzyme immunoassay technique (AN’ALYZA;
BMP-2 immunoassay, TECHNE Co. MN, USA). The dose of
rhBMP-2 used in the in vivo experiments (20 mg) was chosen
for the release study. Twelve BMP/PLAePEG/IP-CHA
composites, which were prepared in the same way as
those used for implantation in the rabbit model, were placed
within 24-well plates together with 500 ml of phosphate-
buffered saline [(PBS) Sigma] and incubated for 21 days at
37(C. The supernatant was removed and replaced with
fresh PBS every day. The supernatants removed on days 1,
3, 7, 14 and 21 were analyzed for their concentrations of
rhBMP-2 according to the enzyme-linked immunosorbent
assay (ELISA) technique. The bioactivity of the composites
maintained in vitro for 0, 7 and 21 days (four samples per
time point) was also assessed (see next section).
IN VIVO BIOASSAY FOR THE BMP/PLA–PEG/IP-CHA
COMPOSITE
To assess the biological activity of composites that were
maintained in vitro for 0, 7 and 21 days, these, as well as
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within the back muscles of 5-week-old male JCL: ICR mice
(one composite per animal; four mice per group, i.e.,
control, day 1, day 7 and day 21) as previously
reported27,28. The implants were harvested 2 weeks after
implantation. They were then crushed, homogenized in
0.2% Nonidet P-40 containing 1 mM MgCl2, and centrifuged
at 10,000 rpm for 1 min at 4(C. The supernatants were
assayed for alkaline phosphatase (ALP) activity using p-
nitrophenyl phosphate as a substrate. The product was
measured spectrophotometrically at an absorption wave-
length of 410 nm (nZ 4 per group)37.
ANIMAL EXPERIMENTS
Fifty-two New Zealand White rabbits weighing 2.5e3.0 kg
(4e6 months) were kept in cages and had free access to
food pellets and water. The rabbits were anesthetized by
the intravenous injection of 1 ml of pentobarbital [50 mg/ml
(Nembutal; Dainippon Pharmaceutical Co. Ltd., Osaka,
Japan)] and the intramuscular injection of 1 ml of xylazine
hydrochloride [25 mg/ml (Seractal; Bayer, Germany)].
After shaving, disinfection, and draping, a straight 3-cm
long medial parapatellar incision was made over the right
knee and the patella was everted. Full-thickness articular
osteochondral defects, 4 mm in diameter and 6 mm in
depth, were created mechanically in the patellar groove of
the right distal femur. Rabbit knees were divided into four
implant groups: group I (nZ 16 knees) received the BMP/
PLAePEG/IP-CHA composite; group II (nZ 12 knees)
received the PLAePEG/IP-CHA composite (no rhBMP-2),
group III (nZ 12 knees) received IP-CHA alone; and group
IV (nZ 12 knees) underwent a sham operation with no
implantation. In groups I, II, and III, all implants were placed
at the subchondral bone level, 2 mm beneath the surface of
the adjacent cartilage. The fascial layer was closed with
absorbable sutures, and the skin with 4-0 nylon sutures.
One week after surgery, four rabbits in group I were killed.
At 3 weeks, 24 rabbits were killed (group IZ 6, group
IIZ 6, group IIIZ 6, group IVZ 6), and at 6 weeks 24
rabbits were killed (group IZ 6, group IIZ 6, group IIIZ 6,
group IVZ 6). The animals were killed by an intravenous
injection of 5 ml of pentobarbital (Table I). All animal
experiments were approved by the Animal Laboratory,
Faculty of Medicine, Osaka University, Japan.
RADIOGRAPHIC AND HISTOLOGICAL EVALUATIONS
The harvested tissues were radiographed using a soft
X-ray apparatus [35 kV; 300 mA; 300 s; MX20 (Faxitron
Table I
Information respecting the deployment of the 52 rabbits used in this
study
Number of rabbits Total
number
Group I Group II Group III Group IV
Materials
IP-CHA C C C 
rhBMP-2 C   
PLAePEG C C  
Follow-up time
1 week 4 0 0 0 4
3 weeks 6 6 6 6 24
6 weeks 6 6 6 6 24
Total number 16 12 12 12 52X-ray Co., IL, USA)] and then ﬁxed in 4% paraformaldehyde
(pH 7.4) for 48 h at 4(C. Tissue samples were decalciﬁed in
20% ethylenediaminetetraacetic acid (pH 7.4) at 4(C,
dehydrated in a graded ethanol series and embedded in
parafﬁn. Serial sections (5 mm in thickness) were cut
sagittally through the center of the operative site and
stained with hematoxylin and eosin (H&E) or with safranin-
O. For the immunohistochemical analysis, parafﬁn sections
were treated with 3% H2O2 to block endogenous peroxi-
dase activity. They were pretreated with serum to block
non-speciﬁc staining. The sections were then incubated
with mouse monoclonal antibodies: anti-type-I collagen
(I-8H5, Daiichi Fine Chemical Co., Ltd, Toyama, Japan),
anti-type-II collagen (II-4C11, Daiichi Fine Chemical Co.,
Ltd, Toyama, Japan), and anti-CD105 [(Endoglin) 555722,
BD Bioscience, NJ, USA]; and with the polyclonal antibody
goat anti-Cbfa1 [(Runx2) C-19, Santa Cruz, CA, USA]38.
The specimens were treated with the appropriate biotiny-
lated secondary antibodies, and then incubated with the
streptavidin/horseradish peroxidase complex. The signal
was visualized as the red reaction product of a 3-amino-9-
ethyl carbazole liquid substrate chromogen (AEC, DAKO
JAPAN Co., Ltd, Kyoto, Japan). To conﬁrm the speciﬁcity of
Table II
Histological scoring system*
Category Points
Cell morphology
Hyaline cartilage 4
Mostly hyaline cartilage 3
Mostly ﬁbrocartilage 2
Mostly non-cartilage 1
Non-cartilage only 0
Matrix-staining (metachromasia)
Normal 3
Slightly reduced 2
Markedly reduced 1
No metachromatic staining 0
Structural integrity
Normal 2
Slight disruption 1
Severe disintegration 0
Surface regularityy
Smooth 3
Moderate 2
Irregular 1
Severely irregular 0
Thickness of cartilage, %
121e150 1
81e120 2
51e80 1
0e50 0
Regenerated subchondral bone
Good 2
Moderate 1
Poor 0
Integration with adjacent cartilage
Both edges integrated 2
One edge integrated 1
Neither edge integrated 0
Total maximum 18
*A modiﬁed version of the system described by Wakitani et al.8.
yTotal smooth area of repair cartilage compared with the entire
area of the cartilaginous compartment of the defect.
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the speciﬁcity of the markers in target cells, all antibodies
were tested for their reactivity in control tissues.
HISTOLOGICAL SCORING
To quantify the histological repair of articular cartilage
defects, we employed a modiﬁed version of the grading
scale described by Wakitani et al.8. This consists of seven
categories and assigns a score ranging from 0 to 18 points
(Table II). The following parameters were assessed: cell
morphology (hyaline cartilage); metachromatic staining of
the cartilage matrix; structural integrity of the regenerated
cartilage; surface regularity of the tissue; thickness of the
cartilage layer; regeneration of the subchondral bone; and
integration of the tissue with adjacent cartilage.
STATISTICAL ANALYSES
Data pertaining to ALP activity were analyzed using an
unpaired Student’s t test. The histological scoring data were
analyzed using the KruskaleWallis test, with a post hoc
Bonferroni correction for non-parametric data.
Results
EVALUATION OF THE IMPLANTS
Scanning electron microscopy of IP-CHA samples
revealed these to have a ﬁnely organized three-dimensional
structure. Most of the IP-CHA pores were spherical, of
similar size (approximately 100e200 mm in diameter) and
uniformly interconnected via channels [10e80 mm in di-
ameter; Fig. 1(B, C)]. Scanning electron microscopy of the
BMP/PLAePEG/IP-CHA composite revealed the BMP/
PLAePEG component to affect neither the pore size northe interconnecting pore structure and to coat well the
surface of the IP-CHA [Fig. 1(D, E)].
IN VITRO RELEASE KINETICS OF RHBMP-2 AND IN VIVO
BIOASSAY FOR THE BMP/PLA–PEG/IP-CHA COMPOSITE
Based on ELISA, the BMP/PLAePEG/IP-CHA composite
released signiﬁcant quantities of rhBMP-2 during the 21-day
monitoring period [6.85G 1.31 mg/ml on day 1,
0.79G 0.22 mg/ml on day 3, 22.9G 0.62 ng/ml on day 7,
4.76G 1.13 ng/ml on day 14, and 2.71G 0.70 ng/ml on day
21; Fig. 2(A)].
To assess the bioactivity of the BMP/PLAePEG/IP-CHA
composites maintained in vitro for 0, 7 or 21 days, we
implanted these, as well as IP-CHAs (control for the
absence of rhBMP-2) within the back muscles of male
ICR mice (a standard ectopic bone-formation model) and
then analyzed the explanted material for its ALP activity.
High levels of ALP activity could be detected even on day
21 [Fig. 2(B)], which accords with the rhBMP-2 release
kinetics results in vitro.
MACROSCOPIC OBSERVATIONS OF CARTILAGE DEFECTS
Three weeks after implantation, the repaired defects in
group I had a macroscopically smooth and glistening
appearance and exhibited continuity with the surrounding
host cartilage [Fig. 3(A)]. The controls (groups IIeIV)
revealed varying degrees of cartilage resurfacing with
ﬁbrous tissue [Fig. 3(BeD)].
At 6 weeks, the color and the glistening appearance of
the repaired defects in group I were similar to those
manifested by the adjacent host cartilage. The junction
between the repaired tissue and the surrounding host
cartilage was not clearly visible [Fig. 3(E)]. In contrast, the
regenerated tissue in the control groups (groups IIeIV) wasFig. 1. Macroscopic photograph (A) and scanning electron micrographs (BeE) of IP-CHA specimens (4 mm in diameter and 4 mm in height).
(A) Macroscopically, the surface of IP-CHA is slightly rough compared with that of other commercial porous hydroxyapatite materials, owing to
its regular porous structure. (B, C) Scanning electron micrographs of IP-CHA, illustrating the regular arrangement of pores which are of similar
size (100e200 mm in diameter), uniformly connected with each other, and separated by thin walls. (B)Z 80!; (C)Z 600!. (D, E) Scanning
electron micrographs of the BMP/PLAePEG/IP-CHA composite. (D) The dark areas lining the pores (white arrows) represent the BMP/
PLAePEG component. The introduction of BMP/PLAePEG had no effect on either the pore size or the interconnecting pore structure. (E)
Higher magniﬁcation of the lining of a pore (black arrow), revealing it to be well coated with BMP/PLAePEG. (D)Z 300!; (E)Z 1000!.
409Osteoarthritis and Cartilage Vol. 13, No. 5ﬁbrous, and had a rough surface containing many ﬁssures
[Fig. 3(FeH)].
RADIOGRAPHIC EVALUATION
Six weeks after implantation, the soft X-ray analysis
revealed defects treated with the BMP/PLAePEG/IP-CHA
composite (group I) to be consistently ﬁlled with newly
formed bone, which was continuous with the surrounding
intact subchondral bone [Fig. 3(I)]. In the control groups
(groups IIeIV), bone formation was incomplete and irregular
[Fig. 3(JeL)].
HISTOLOGICAL EVALUATION
One week after implantation with the BMP/PLAePEG/
IP-CHA composite (group I), vigorous new bone formation
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Fig. 2. Time courseof rhBMP-2 release from theBMP/PLAePEG/IP-
CHA composite in vitro (A) and the bioactivity of the composites in
vivo (B). (A) Release kinetics (measured by ELISA) of rhBMP-2 from
the BMP/PLAePEG/IP-CHA composite, illustrating signiﬁcant quan-
tities of rhBMP-2 during the 21-day monitoring period. The bar graph
depicts the non-cumulative release at each time point. Mean
valuesG SD (nZ 4) are represented. (B) The bioactivity of BMP/
PLAePEG/IP-CHA composites that were maintained in vitro for
0 (D0), 7 (D7), or 21 (D21) days was assessed 2 weeks after their
implantation at an ectopic site in mice by monitoring the ALP activity
of the explanted material. PLAePEG/IP-CHA (no rhBMP-2) repre-
sented the control. High levels of ALPactivity could be detected even
on day 21 [86.8G 23.2 mmol/min/disc (day 0), 40.3G 16.8 mmol/
min/disc (day7), 17.7G 5.2 mmol/min/disc (day21), 1.6G 0.8 mmol/
min/disc (control)]. Mean valuesG SD (nZ 4) are represented.
*Z value is signiﬁcantly different from the control (P! 0.05).was observed histologically within the pores of the IP-CHA
scaffold [Fig. 4(B)], and about three-quarters of the defect
depth above the IP-CHA had already been replaced with
repair tissue. The central part of the repair tissue
contained a ﬁbrin clot and a few vessels. The lateral and
lower regions consisted of granulation tissue, which was
actively undergoing neovascularization and contained
rounded ﬁbroblast-like cells. These cells registered posi-
tive for Cbfa1 and/or CD105. They appeared to have
inﬁltrated from the surrounding intact subchondral bone,
either directly, or indirectly via the interconnecting IP-CHA
pores, which were likewise ﬁlled with granulation
tissue. Some of the pores in the peripheral 1-mm portions
of IP-CHA blocks already contained newly formed bone
(Fig. 4).
Three weeks after implantation with BMP/PLAePEG/
IP-CHA, the defect space above the IP-CHA blocks
(subchondral space) was ﬁlled with newly generated and
vigorous bone tissue, which penetrated the interconnecting
pores of this material [Fig. 5(A, F)]. The regenerated
articular cartilage was more cellular and contained less
extracellular matrix than normal cartilage. The regenerated
cartilage was divided into three distinct zones: (1)
a superﬁcial one, which contained ﬂattened hyperchro-
matic cells; (2) a middle one, which contained rounded
chondrocytes; and (3) a zone of enchondral ossiﬁcation.
The cartilage-like layer was two-to-three times thicker than
normal cartilage [Fig. 5(A, E)]. In each of the control
groups (groups IIeIV), the regenerated ﬁbrous cartilage
had a similar morphological appearance, irrespective of
the absence or presence of an implant. Although the
subchondral space in group II tended to be ﬁlled with more
newly formed bone than did that in the other control
groups (groups III and IV), the quantitative histological
evaluation revealed no signiﬁcant difference between them
[Table III; Fig. 5(BeD)].
Six weeks after implantation, defects treated with the
BMP/PLAePEG/IP-CHA composite (group I) were ﬁlled
with regenerated subchondral bone, which also penetrated
the pores of the implant. The subchondral bone was
covered with a layer of regenerated cartilage tissue of
almost normal thickness. The hyaline nature of the
cartilage was maintained, and the tissue was beginning
to assume a columnar organization and a horizontal
stratiﬁcation into four distinct zones (superﬁcial, middle,
deep and calciﬁed), as in normal cartilage [Fig. 6(A, E)].
Interestingly, no gaps could be distinguished microscopi-
cally between the host cartilage and the newly regener-
ated cartilage, which suggests that the tissues were
functionally and biologically integrated [Fig. 6(F)]. Safra-
nin-O staining was evident predominantly in the middle
and deep zones. Immunoreactivity for type-II collagen
tended to be weakest in the deep zone at the junction with
host tissue. But generally, the matrix exhibited a hyaline-
like cartilaginous phenotype [registering negative for type-I
collagen; Fig. 6(JeL)]. In contrast, defects in the control
groups (groups IIeIV) were ﬁlled with a hypercellular type
of ﬁbrous tissue. No hyaline cartilage was detected,
despite the presence of new bone above and within the
implant; [Fig. 6(BeD, GeI)]. Histological sections were
assessed quantitatively using a modiﬁed version of an
established grading system, which measures the degree
and quality of cartilage repair8 (Table II). At each time
point, the scores for the BMP/PLAePEG/IP-CHA compos-
ite (group I) were signiﬁcantly better than those for groups
II, III and IV (P! 0.01). These ﬁndings accord with the
macroscopic and histological observations.
410 N. Tamai et al.: Articular cartilage repairFig. 3. Gross appearance (AeH) and soft X-ray photographs (IeL) of four specimens (one in each group) 3 weeks (AeD) and 6 weeks (EeL)
after implantation. (A, E, I): BMP/PLAePEG/IP-CHA composite (group I). (B, F, J): PLAePEG/IP-CHA composite (group II). (C, G, K): IP-CHA
alone (group III). (D, H, L): no implant (group IV). (A, E) In group I, reconstruction of the surface was good. At 3 weeks, the surface was still
a little ‘‘white’’; but at 6 weeks, it was smooth and glistening and exhibited continuity with the surrounding intact host cartilage. These
macroscopic ﬁndings correspond with the histological results (Table III). (B, F) In group II, the articular cartilage defects were covered with
‘‘white’’ ﬁbrous tissue with many ﬁssures. (C, G) In group III, the regeneration of the defect looked better than those of other control groups
(group II and IV), whereas the junction of the defects were still visible. (D, H) In group IV, in which the defects were left empty, at 3 weeks the
defects were ﬁlled with red, semitransparent tissue with the margins sharply deﬁned and the edges completely discernible (D). At 6 weeks, the
defects were ﬁlled with irregular ‘‘white’’ tissue with pin-hole like ﬁssure (H). (IeL) Representative soft X-ray photographs of the four
specimens. The black arrows denote the implanted IP-CHA block. The white arrows above the IP-CHA block indicate the region where
subchondral bone should be regenerated. A white, radiodense zone was observed above the IP-CHA block in group I (I); it denotes a vigorous
regeneration of subchondral bone. This radiodense zone was not detected in groups IIeIV (JeL).Discussion
Several investigators have reported on the repair of
articular cartilage defects using diverse tissue-engineering
approaches. These include a gene-enhanced technique,
the direct implantation of growth factors, and in vitro cell
expansion39e42. BMPs have been shown to induce the
differentiation of MSCs into chondrocytes both in vitro and
in vivo. BMPs (BMP-2 and BMP-7) have also been used in
conjunction with type-I collagen sponges to elicit the repair
of osteochondral defects43e45. Cook et al.40 have reported
that type-I collagen sponges impregnated with rhBMP-7 can
induce the repair of full-thickness osteochondral defectswith hyaline-like cartilage in a dog model. The hyaline-like
quality of the repair cartilage was still evident 52 weeks after
surgery and the tissue had undergone no signiﬁcant
degradation. Sellers et al.41 have demonstrated the
capacity of rhBMP-2 to accelerate the healing of full-
thickness articular cartilage defects and to improve the
histological appearance and the biochemical characteristics
of the repair cartilage. However, the tissue still differed from
normal hyaline cartilage, both biochemically and structur-
ally, and a long time elapsed before the defect area was
completely ﬁlled with it. These suboptimal results probably
reﬂect a limited recruitment of MSCs and/or a restricted
delivery of cytokines, owing to the poor structural
411Osteoarthritis and Cartilage Vol. 13, No. 5Fig. 4. Histological photomicrographs of a defect 1 week after the implantation of a BMP/PLAePEG/IP-CHA composite (group I). (A) Overview
of the defect site, the margins of which are indicated by arrows. HA represents the implanted IP-CHA scaffold (H&E). (B) Higher magniﬁcation
of the region indicated in (A). The surface of newly formed bone trabeculae are lined with numerous cuboidal osteoblasts which have migrated
from the neighboring host bone. (C) Higher magniﬁcation of the region indicated in (A), illustrating a neovascularized aggregate of cells which
have migrated from the neighboring bone marrow, either directly or indirectly via the interconnecting channels of the IP-CHA composite. The
arrowheads in (B) and (C) indicate the interconnecting pores of the IP-CHA scaffold. The asterisks denote regions that were occupied by
hydroxyapatite before decalciﬁcation. (D) Higher magniﬁcation of (C), illustrating the rounded, ﬁbroblast-like form of the aggregated cells.
(E, F) Immunostaining of the aggregated cells for Cbfa1 (E) and CD105 (F). Many of the cells expressed the chondro/osteoblastic marker (E)
and/or the mesenchymal one (F). Magniﬁcation: (A)Z 10!; (B, C)Z 100!; (E, F)Z 200!; (D)Z 400!.
412 N. Tamai et al.: Articular cartilage repairFig. 5. Histological photomicrographs of defects (H&E staining) 3 weeks after implantation with either the BMP/PLAePEG/IP-CHA composite
[(group I) A, E, F], the PLAePEG/IP-CHA composite [(group II) B], or IP-CHA alone [(group III) C], and in the absence of treatment [empty (group
IV) D]. Arrows indicate the margins of the defect. HA represents the implanted IP-CHA scaffold. Highly magniﬁed images of the regions indicated
in (A) are represented in (E) and (F). (A) Section of a defect ﬁlled with the BMP/PLAePEG/IP-CHA composite (group I), illustrating well-organized
hyaline-like cartilage and accelerated replacement of vigorous subchondral bone. (BeD) In each of the control groups (group IIeIV), the
regenerated tissue had a similar morphological appearance, irrespective of the absence or presence of an implant. The defect site was ﬁlled
predominantly with a hypocellular ﬁbrocartilage repair tissue with incomplete replacement of subchondral bone. (E) The regenerated articular
cartilage was more cellular and contained less extracellular matrix than normal cartilage. However, a stratiﬁed structure similar to normal cartilage
was already visible. (F) Vigorous regeneration of subchondral bone occurred, which was carried up through the interconnections of the IP-CHA
scaffold (arrowheads). The asterisk denotes a region that was occupied by hydroxyapatite before decalciﬁcation. Magniﬁcation: (AeD)Z 10!;
(E, F)Z 100!.organization of the supporting scaffold. The purpose of the
present study was to evaluate the potential of IP-CHA to
serve as a scaffold for the repair of full-thickness articular
cartilage defects. This material has a well-organized inter-
pore connectivity.
The osteoconductivity of polymer implants containing
rhBMP-2 has been studied extensively28,46. In the present
study, we used the synthetic bioabsorbable polymer
PLAePEG as a carrier for rhBMP-2. In vitro, rhBMP-2
was released continuously from theBMP/PLAePEG/IP-CHA
composite over a period of 21 days, as determined by
ELISA [Fig. 2(A)]. This ﬁnding accords with the results of
the in vivo bioassay [Fig. 2(B)], which was based on the
ALP activity of composites implanted at an ectopic site in
mice. However, it is of course conceivable that the release
proﬁle of rhBMP-2 at this ectopic site in mice differs greatly
from that at the orthotopic site in our rabbit model.
Our new strategy for articular cartilage repair appears to
be unique in three respects: (1) autogenous MSCs wereefﬁciently recruited from the bone marrow by strongly
activating regeneration within the subchondral bone com-
partment of the defect; (2) a sustained BMP stimulus
appears to promote not only the vigorous regeneration of
subchondral bone but also the ensuing differentiation of
chondrocytes and the production of a cartilaginous matrix at
the surface, which results in the regeneration of a hyaline-
like cartilage layer in as short a time as 3 weeks; and (3) the
regenerated cartilage integrated almost perfectly with the
surrounding host cartilage, probably because the entire
regeneration process was conducted in situ, i.e., it did not
involve an in vitro chondrocyte-culturing step.
It is not known why the thickness of the repaired articular
cartilage corresponded so closely to that of the host
articular cartilage, with no bony differentiation. But articular
factors, such as oxygen tension, joint effusion and
mechanical stress, as well as subchondral inﬂuences,
may regulate the differentiation process. Although the
regenerated cartilage present 6 weeks after surgery was
413Osteoarthritis and Cartilage Vol. 13, No. 5microscopically so well integrated with the surrounding host
cartilage, the histological analysis revealed a slight discrep-
ancy between safranin-O staining and immunoreactivity for
type-II collagen [Fig. 6(J, L)]. This may be accounted for by
the fact that chondrocytes near the junction with host
cartilage produced less matrix than did those located more
centrally within the regenerated tissue, where staining with
Fig. 5. (continued).safranin-O was absent only from the superﬁcial zone, as in
normal articular cartilage.
Cbfa1, a member of the Runt-domain family of transcrip-
tional factors, is expressed not only in all osteoblasts, but
also in chondrocytes and in earlier prechondrogenic
mesenchymal condensations47e49. Furthermore, Cbfa1 is
known to play an essential role in the differentiation not only
of osteoblasts but also of chondrocytes, both at an early
and a later stage of the process50,51. CD105 is a putative
cell-surface marker for MSCs, which have the ability to
undergo chondrogenesis, osteogenesis and adipogene-
sis52,53. One week after implantation, numerous cuboidal
osteoblasts migrated into the pores of the IP-CHA scaffold
from the host bone marrow (Fig. 3). And within peripheral
pores, they had already begun to form bone tissue. The
subchondral space above the IP-CHA scaffold was ﬁlled
with an agglomeration of rounded ﬁbroblast-like cells, which
registered positive for Cbfa1 and/or CD105. They appeared
to have migrated from the adjacent bone marrow, either
directly, or indirectly via the interconnecting pores of the
IP-CHA. These ﬁndings suggest that the aggregating
ﬁbroblast-like cells might have the potential for chondro/
osteogenesis.
According to our ﬁndings, one of the keys to successful
articular cartilage regeneration might be the activation of
a subchondral repair process, thereby enabling chondro-
blastic/osteoblastic cells to effectively aggregate within the
subchondral space. In rabbits, small, 3-mm-diameter, full-
thickness articular cartilage defects heal spontaneously
with repair tissue, which is composed of hyaline-like or
ﬁbrous cartilage. In adolescent rabbits (approximately 3
months old), osteochondral defects repair better and more
rapidly than do those in adults34,54. Furthermore, adoles-
cent rabbits have a larger population of metabolically active
bone-marrow MSCs. Hence, in the present study, we
established a large (4-mm-diameter) full-thickness defect
model, it being necessary to exceed the upper limit (3 mm in
diameter) for spontaneous repair. And since our system
involved no cell-expansion step in vitro, the adolescent
(rather than the adult) rabbit model was considered to be
advantageous in its possession of a larger population of
metabolically active bone-marrow MSCs.
A basic requirement for biomaterials is that they be non-
carcinogenic and elicit no inﬂammatory reaction due to
cytotoxicity or immunogenicity55. The BMP/PLAePEG/IP-
CHA composite is believed to meet these criteria. The PLA
and PEG homopolymers and hydroxyapatite have been
shown to be compatible and safe for clinical applica-
tions30,56. In addition to these safety features, it is crucial
that biomaterials are easy to handle in clinical settings.Table III
Results of the histological scoring
Group No. of
defects
Cell
morphology
Matrix-staining Structural
integrity
Surface
regularity
Thickness Reconstruction
of subchondral
bone
Integration with
adjacent
cartilage
Total
score
Group I: 3 weeks 6 3.6G 0.5* 2.0G 0 1.3G 0.5 2.0G 0.9 1.2G 0.4 0.8G 0.7 1.8G 0.4x 12.8G 2.4*
Group II: 3 weeks 6 1.7G 0.5 1.0G 0.6 0.5G 0.5 0.5G 0.5 0.7G 0.5 0.5G 0.4 1.0G 0.6x 5.8G 2.6
Group III: 3 weeks 6 2.2G 0.8 1.3G 0.5 0.5G 0.5 0.7G 0.4 1.0G 0 0.5G 0.4 1.2G 0.8x 7.2G 2.2
Group IV: 3 weeks 6 1.3G 0.5 0.8G 0.4 0.7G 0.5 1.3G 0.5 0.5G 0.3 0.5G 0.3 0.5G 0.3 5.1G 1.1
Group I: 6 weeks 6 3.8G 0.4* 2.3G 0.5* 1.5G 0.5x 2.2G 1.0 1.2G 0.4x 1.8G 0.4x 1.5G 0.5 15.0G 2.1*
Group II: 6 weeks 6 1.8G 0.4 1.5G 0.5 1.2G 0.4 1.5G 0.5 1.2G 0.4 1.3G 0.5x 1.2G 0.4 9.7G 1.2
Group III: 6 weeks 6 1.7G 1.0 1.0G 0.8 0.8G 0.4 1.7G 0.5 0.7G 0.5 1.3G 0.5x 1.2G 0.4 8.3G 3.0
Group IV: 6 weeks 6 1.5G 0.5 0.5G 0.4 0.5G 0.5 1.3G 0.5 0.7G 0.5 0.5G 0.3 0.8G 0.4 5.7G 1.9
Values represent the average scoreG SD for each category. *P! 0.01 vs groups II, III, and IV. xP! 0.01 vs group IV.
414 N. Tamai et al.: Articular cartilage repairFig. 6. Histological photomicrographs of defects 6 weeks after implantation with either the BMP/PLAePEG/IP-CHA composite [(group I) A, E,
F, JeL], the PLAePEG/IP-CHA composite [(group II) B, G], or IP-CHA alone [(group III) C, H], and in the absence of treatment [empty (group
IV) D, I]. Arrows indicate the margins of the defect. HA represents the implanted IP-CHA scaffold. Highly magniﬁed images of the regions
indicated in (AeD) are represented in (EeI). (A) The defect treated with the BMP/PLAePEG/IP-CHA composite (group I) was ﬁlled with
regenerated subchondral bone, which also penetrated the pores of the implant. The subchondral bone was covered with a layer of
regenerated cartilage tissue of almost normal thickness. (B, C) In the control groups (group II and III), the defects were ﬁlled with
a hypercellular type of ﬁbrous tissue with regeneration of subchondral bone. The surface the repaired tissue was rough. (D) Without treatment
(group IV), the defect site was predominantly replaced by thick ﬁbrocartilage tissue with a thin layer of irregular subchondral bone. (E) The
central region of the regenerated articular cartilage layer (group I). The repaired tissue has a hyaline-like appearance and is undergoing
organization into vertical columns. The four horizontal strata characteristic of normal articular cartilage are apparent. (F) The junction between
host and regenerated cartilage is continuous, and very little ﬁbrillation of the articular surface is apparent (group I). (GeI) The repaired tissue
is mainly of a ﬁbrous nature (group IIeIV). (JeL) Safranin-O staining (J), and immunostaining for type-I collagen (K) and type-II collagen (L) at
the junction between host and the regenerated cartilage (group I). Magniﬁcation: (AeD)Z 10!; (EeI)Z 100!; (JeL)Z 40!. (AeI):
H&E staining.Current techniques using cultured chondrocyte suspen-
sions or collagen gels are complicated by problems
associated with cell retention. Our composite material
circumvents these problems. Furthermore, our material
may be shaped into a ‘‘ready-to-use’’ form. It is possible to
adjust its size and shape to suit the dimensions of the defect
prior to implantation.
In conclusion, we have successfully induced the repair of
articular cartilage defects within a relatively short period of
time by combining rhBMP-2 with two biomaterials: IP-CHA
as a scaffold and PLAePEG as a carrier for rhBMP-2. The
BMP/PLAePEG/IP-CHA composite represents a new and
promising technology for the engineering of articular
cartilage. Clinical applications for the treatment of both
osteoarthritis and articular cartilage injuries are alsoanticipated. Further studies involving long-term observa-
tions in both adolescent and adult animals are currently
underway.
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